BioCentury | Dec 31, 2020
Distillery Therapeutics

Host-directed inhibitors against the SKI complex to inhibit coronavirus, influenza, Ebola, Marburg viruses

...Acad. Sci. USA; published online Nov. 12, 2020doi:10.1073/pnas.2012939117CONTACT: Matthew B. Frieman, University of Maryland School of Medicine, Baltimore, Md.email: mfrieman@som.umaryland.edu Claire Quang University of Maryland Infectious Coronavirus Influenza...
BioCentury | Oct 1, 2020
Politics, Policy & Law

Offit, McClellan testimonies aim to bolster trust in COVID-19 vaccine developers, review process

...hearing about how vaccine developers are measuring efficacy, citing a Sept. 22 op-ed in The New York Times by Scripps Research’s Eric Topol and University of Maryland’s Peter...
BioCentury | Jul 8, 2020
Product Development

NIH, Warp Speed streamline preventive mAb, vaccine testing via clinical trial network

...researcher Larry Corey, and Kathleen Neuzil, director of the Center for Vaccine Development at the University of Maryland...
BioCentury | Jun 9, 2020
Deals

AstraZeneca eyes August trial start for COVID-19 mAb pair

...partnered with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the University of Maryland...
BioCentury | Apr 9, 2020
Product Development

AZ’s Pangalos: what the pharma brings to COVID-19 fight, and where it turns to others

...and partnering with United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the University of Maryland...
BioCentury | Mar 28, 2020
Translation in Brief

17 FDA-approved drugs show activity against SARS-CoV-2; two groups seek COVID-19 patient-derived mAbs; plus NYU, Scholar Rock and LIfT-King's College

...Maryland team highlights 17 approved drugs that could be repurposed for COVID-19 A University of Maryland team identified...
...Interleukin-10 TGFβ1 - Transforming growth factor β 1 BioCentury Staff Berkeley Lights Inc. New York University Langone Medical Center University of Maryland King's...
BioCentury | Aug 31, 2019
Product Development

Rethinking first principles

...changes and is personalized?” Ameet Nathwani, Sanofi   A publication in Diabetes Care from the University of Maryland...
...Pear Therapeutics Inc., Boston, Mass. Sanofi (Euronext:SAN; NASDAQ:SNY), Paris, France UCB S.A. (Euronext:UCB), Brussels, Belgium University of Maryland...
BioCentury | Aug 6, 2019
Company News

Newly launched LUCA planning to tackle infections in women

...at the Institute for Genome Sciences and a professor of microbiology and immunology at the University of Maryland...
BioCentury | May 28, 2019
Distillery Therapeutics

CD34-positive melanocyte stem cells for demyelination diseases

...24, 2019 doi: 10.1371/journal.pgen.1008034 CONTACT: Thomas Hornyak, University of Maryland School of Medicine, Baltimore, Md. email: thornyak@som.umaryland.edu Hongjiang Li University of Maryland CD34 Neurology...
BioCentury | Nov 30, 2018
Company News

GEn1E gains rights to MUC1 IP

...exclusive option to license patent rights to mucin 1 (MUC1; CD227) decoy peptides from the University of Maryland...
...would explore using the IP to treat Pseudomonas , including in individuals with cystic fibrosis. University of Maryland...
Items per page:
1 - 10 of 205
BioCentury | Dec 31, 2020
Distillery Therapeutics

Host-directed inhibitors against the SKI complex to inhibit coronavirus, influenza, Ebola, Marburg viruses

...Acad. Sci. USA; published online Nov. 12, 2020doi:10.1073/pnas.2012939117CONTACT: Matthew B. Frieman, University of Maryland School of Medicine, Baltimore, Md.email: mfrieman@som.umaryland.edu Claire Quang University of Maryland Infectious Coronavirus Influenza...
BioCentury | Oct 1, 2020
Politics, Policy & Law

Offit, McClellan testimonies aim to bolster trust in COVID-19 vaccine developers, review process

...hearing about how vaccine developers are measuring efficacy, citing a Sept. 22 op-ed in The New York Times by Scripps Research’s Eric Topol and University of Maryland’s Peter...
BioCentury | Jul 8, 2020
Product Development

NIH, Warp Speed streamline preventive mAb, vaccine testing via clinical trial network

...researcher Larry Corey, and Kathleen Neuzil, director of the Center for Vaccine Development at the University of Maryland...
BioCentury | Jun 9, 2020
Deals

AstraZeneca eyes August trial start for COVID-19 mAb pair

...partnered with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the University of Maryland...
BioCentury | Apr 9, 2020
Product Development

AZ’s Pangalos: what the pharma brings to COVID-19 fight, and where it turns to others

...and partnering with United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the University of Maryland...
BioCentury | Mar 28, 2020
Translation in Brief

17 FDA-approved drugs show activity against SARS-CoV-2; two groups seek COVID-19 patient-derived mAbs; plus NYU, Scholar Rock and LIfT-King's College

...Maryland team highlights 17 approved drugs that could be repurposed for COVID-19 A University of Maryland team identified...
...Interleukin-10 TGFβ1 - Transforming growth factor β 1 BioCentury Staff Berkeley Lights Inc. New York University Langone Medical Center University of Maryland King's...
BioCentury | Aug 31, 2019
Product Development

Rethinking first principles

...changes and is personalized?” Ameet Nathwani, Sanofi   A publication in Diabetes Care from the University of Maryland...
...Pear Therapeutics Inc., Boston, Mass. Sanofi (Euronext:SAN; NASDAQ:SNY), Paris, France UCB S.A. (Euronext:UCB), Brussels, Belgium University of Maryland...
BioCentury | Aug 6, 2019
Company News

Newly launched LUCA planning to tackle infections in women

...at the Institute for Genome Sciences and a professor of microbiology and immunology at the University of Maryland...
BioCentury | May 28, 2019
Distillery Therapeutics

CD34-positive melanocyte stem cells for demyelination diseases

...24, 2019 doi: 10.1371/journal.pgen.1008034 CONTACT: Thomas Hornyak, University of Maryland School of Medicine, Baltimore, Md. email: thornyak@som.umaryland.edu Hongjiang Li University of Maryland CD34 Neurology...
BioCentury | Nov 30, 2018
Company News

GEn1E gains rights to MUC1 IP

...exclusive option to license patent rights to mucin 1 (MUC1; CD227) decoy peptides from the University of Maryland...
...would explore using the IP to treat Pseudomonas , including in individuals with cystic fibrosis. University of Maryland...
Items per page:
1 - 10 of 205